Neuland Laboratories Stock Screener | Share Price & Fundamental Analysis
NEULANDLAB
Pharmaceuticals
Share Price NSE
₹12638.00
▼
-382.00 (-2.93%)
Share Price BSE
₹12654.10
▼
-375.35 (-2.88%)
Track Neuland Laboratories share price live with TickJournal's free stock screener.
Analyze Neuland Laboratories share price history trends and compare 52-week high low
levels.
Calculate NEULANDLAB stock fair value using fundamental analysis and view live share price charts.
Determine Neuland Laboratories share intrinsic value and compare it with current NEULANDLAB share price.
Record your Neuland Laboratories trades in TickJournal's free trading journal and track your portfolio performance.
Neuland Laboratories Market Cap
₹16,750.70 Cr.
EPS (TTM)
₹202.74
Dividend Yield
0.09%
Debt to Equity
0.09
NEULANDLAB 52 Week High
₹18113.00
Neuland Laboratories 52 Week Low
₹10487.30
Operating Margin
16.00%
Profit Margin
8.33%
NEULANDLAB Revenue (TTM)
₹336.00
EBITDA
₹59.00
Net Income
₹28.00
Total Assets
₹2,180.00
Total Equity
₹1,525.00
Neuland Laboratories Share Price History - Stock Screener Chart
Screen NEULANDLAB historical share price movements with interactive charts. Analyze price trends and patterns.
Neuland Laboratories Company Profile - Fundamental Screener
Screen Neuland Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for NEULANDLAB shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE794A01010
Neuland Laboratories Balance Sheet Screener
Screen NEULANDLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 2,180 | 1,833 | 1,580 | 1,384 | 1,325 | 1,231 | 1,130 | 1,071 | 886 | 524 |
| Current Assets | 1,140 | 921 | 761 | 581 | 550 | 515 | 454 | 447 | 375 | 314 |
| Fixed Assets | 955 | 824 | 758 | 767 | 716 | 653 | 542 | 475 | 466 | 139 |
| Liabilities | ||||||||||
| Total Liabilities | 2,180 | 1,833 | 1,580 | 1,384 | 1,325 | 1,231 | 1,130 | 1,071 | 886 | 524 |
| Current Liabilities | 189 | 122 | 147 | 180 | 170 | 163 | 104 | 146 | 54 | 69 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 1,525 | 1,283 | 994 | 841 | 787 | 710 | 699 | 558 | 546 | 187 |
| Share Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 9 | 9 | 9 |
| Reserves & Surplus | 1,512 | 1,270 | 981 | 828 | 774 | 697 | 686 | 549 | 537 | 178 |
Neuland Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Neuland Laboratories income statement and profit fundamentals.
Analyze NEULANDLAB quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Neuland Laboratories share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 336 | 301 | 516 | 448 | 390 | 465 | 315 | 458 | 415 | 365 | 421 | 395 | 257 | 222 | 294 |
| Expenses | 277 | 258 | 359 | 363 | 278 | 316 | 249 | 311 | 287 | 266 | 280 | 272 | 217 | 193 | 224 |
| EBITDA | 59 | 42 | 157 | 85 | 112 | 149 | 67 | 146 | 128 | 99 | 141 | 123 | 40 | 29 | 70 |
| Operating Profit % | 16.00% | 12.00% | 30.00% | 18.00% | 28.00% | 28.00% | 20.00% | 22.00% | 29.00% | 27.00% | 33.00% | 31.00% | 15.00% | 13.00% | 24.00% |
| Depreciation | 17 | 20 | 23 | 24 | 17 | 16 | 16 | 16 | 14 | 14 | 15 | 15 | 12 | 13 | 13 |
| Interest | 2 | 5 | 5 | 7 | 4 | 3 | 1 | 2 | 4 | 2 | 4 | 4 | 3 | 3 | 3 |
| Profit Before Tax | 39 | 18 | 129 | 55 | 92 | 130 | 49 | 128 | 110 | 83 | 122 | 105 | 24 | 14 | 53 |
| Tax | 12 | 4 | 33 | 14 | 25 | 32 | 17 | 26 | 26 | 21 | 32 | 23 | 3 | 4 | 15 |
| Net Profit | 28 | 14 | 97 | 41 | 68 | 98 | 33 | 102 | 85 | 62 | 89 | 81 | 22 | 10 | 39 |
| EPS | 21.67 | 10.83 | 75.49 | 31.62 | 52.66 | 76.28 | 25.60 | 79.18 | 65.90 | 48.23 | 69.56 | 63.44 | 16.97 | 7.77 | 29.97 |
Neuland Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen NEULANDLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 317 | 261 | 237 | 60 | 189 | 57 | 70 | 11 | 39 | 45 |
| Investing Activities | -298 | -150 | -61 | -95 | -85 | -49 | -77 | -116 | -42 | -20 |
| Financing Activities | 25 | -69 | -136 | 38 | -114 | -6 | 12 | 105 | 0 | -24 |
| Net Cash Flow | 44 | 42 | 40 | 3 | -9 | 3 | 5 | 0 | -4 | 1 |
Neuland Laboratories Shareholding Pattern Screener
See Neuland Laboratories shareholding pattern with promoter, FII, and DII holdings.
Check Neuland Laboratories promoter holding and ownership changes for NEULANDLAB on TickJournal.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 32.63% | 32.64% | 32.68% | 32.68% | 32.68% | 32.64% | 32.72% | 32.74% |
| FII Holding | 20.90% | 20.60% | 21.69% | 22.11% | 23.86% | 26.46% | 25.72% | 24.44% |
| DII Holding | 14.71% | 13.54% | 11.57% | 10.97% | 9.08% | 6.38% | 6.39% | 6.54% |
| Govt Holding | 0.00% | 0.40% | 0.40% | 0.40% | 0.40% | 0.40% | 0.40% | 0.40% |
| Public Holding | 24.31% | 24.72% | 25.55% | 25.86% | 26.05% | 26.50% | 27.05% | 27.97% |
| Other Holding | 7.45% | 8.09% | 8.12% | 7.99% | 7.93% | 7.61% | 7.71% | 7.91% |
| Shareholder Count | 46,187 | 44,393 | 42,419 | 39,333 | 39,315 | 34,567 | 29,077 | 28,616 |
Neuland Laboratories Share Dividend Screener - Share Yield Analysis
Check Neuland Laboratories dividend history with payout and yield data.
View Neuland Laboratories dividend details including ex-dates and amounts for NEULANDLAB stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹12.00 | 0.09% |
| 2024-March | ₹14.00 | 0.12% |
| 2023-March | ₹10.00 | 0.16% |
| 2022-March | ₹5.00 | 0.28% |
| 2021-March | ₹5.00 | 0.49% |
| 2020-March | ₹2.00 | 0.10% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Neuland Laboratories Stock Index Membership
See which indices include Neuland Laboratories stock.
Check NEULANDLAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Neuland Laboratories Market Events Screener - Corporate Actions
Get Neuland Laboratories corporate actions including splits, bonuses, and buybacks.
Check Neuland Laboratories stock events that may affect NEULANDLAB share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-02-09 | 2026-02-09 | Quarterly Result Announcement | NA | -4.05% |
| 2025-11-07 | 2025-11-07 | Quarterly Result Announcement | NA | 8.38% |
| 2025-07-31 | 2025-07-31 | Quarterly Result Announcement | NA | 13.07% |
| 2025-07-30 | 2025-07-30 | Annual General Meeting | NA | 11.04% |
| 2025-07-18 | 2025-07-18 | Dividend | ₹ 12.00 /share | 16.23% |
| 2025-05-15 | 2025-05-15 | Quarterly Result Announcement | NA | -2.72% |
| 2025-02-10 | 2025-02-10 | Quarterly Result Announcement | NA | 2.73% |
| 2024-11-06 | 2024-11-06 | Quarterly Result Announcement | NA | -2.42% |
| 2024-07-31 | 2024-07-31 | Annual General Meeting | NA | 26.65% |
| 2024-07-12 | 2024-07-13 | Dividend | ₹ 14.00 /share | 13.26% |
| 2023-07-11 | 2023-07-12 | Dividend | ₹ 10.00 /share | 41.77% |
| 2022-07-14 | 2022-07-15 | Dividend | ₹ 5.00 /share | -2.72% |
| 2021-06-29 | 2021-07-01 | Dividend | ₹ 3.00 /share | -20.44% |
Neuland Laboratories Competitors Screener - Peer Comparison
Screen NEULANDLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 407,287 | 37.56 | 54,729 | 9.71% | 10,980 | 52.49 |
| Divis Laboratories | 163,754 | 66.27 | 9,712 | 18.67% | 2,191 | 48.87 |
| Torrent Pharmaceuticals | 138,018 | 64.55 | 11,539 | 6.99% | 1,911 | 59.36 |
| Cipla | 107,555 | 23.69 | 28,410 | 7.12% | 5,291 | 35.86 |
| Dr Reddys Laboratories | 105,839 | 19.26 | 33,741 | 16.73% | 5,725 | 58.24 |
| Lupin | 100,464 | 23.23 | 22,910 | 13.74% | 3,306 | 56.93 |
| Zydus Life Science | 91,034 | 18.43 | 23,511 | 18.55% | 4,615 | 51.32 |
| Mankind Pharma | 85,058 | 47.59 | 12,744 | 20.90% | 2,007 | 42.02 |
| Aurobindo Pharma | 66,537 | 19.29 | 32,346 | 9.43% | 3,484 | 45.13 |
| Alkem Laboratories | 64,595 | 29.06 | 13,458 | 3.70% | 2,216 | 36.02 |
Neuland Laboratories Company Announcements - News Screener
Screen NEULANDLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-02-21 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2026-02-19 | Re-Lodgement Of Transfer Request Of Physical Shares | View |
| 2026-02-18 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2026-02-17 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2026-02-17 | Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised) | View |
| 2026-02-17 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2026-02-17 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2026-02-17 | Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025 | View |
| 2026-02-17 | Board Meeting Outcome for Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025 | View |
| 2026-02-12 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-01-30 | Intimation Regarding Conversion Of Statutory AuditorS Firm To A Limited Liability Partnership (LLP) | View |
| 2026-01-27 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-01-21 | Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025 | View |
| 2026-01-02 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2026-01-02 | Re-Lodgement Of Transfer Request Of Physical Shares | View |
| 2025-12-26 | Closure of Trading Window | View |
| 2025-12-19 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-12-15 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-09 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-08 | Re-Lodgement Of Transfer Request Of Physical Shares | View |